Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT05498337 |
Other study ID # |
Vital pulp therapy |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
September 1, 2022 |
Est. completion date |
March 1, 2024 |
Study information
Verified date |
August 2022 |
Source |
Mansoura University |
Contact |
Nada M Abdelkader, As. lecturer |
Phone |
+201006429239 |
Email |
nadaabdelkader86[@]gmail.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
This study will be conducted to:
Evaluate clinically and radiographically apexogenesis in immature permanent molars using:
1. Calcium Hydroxide.
2. MTA.
3. Laser.
4. Laser combined with MTA.
Description:
Calcium Hydroxide has been the most commonly utilized pulpotomy agent for vital pulp therapy.
It is the earliest medicament employed in pulpotomy that possesses the ability to stimulate
tertiary dentinogenesis. This is attributed to its high alkalinity after mixing with water.
Calcium hydroxide has a high pH, and its dental use relates chiefly to its ability to
stimulate mineralization and also to its antibacterial property.
Biocompatibility and sealing ability are the most important properties, which account for
optimal healing response in vital pulp therapy. Unlike conventional materials, MTA has low
solubility and maintains its physical integrity after placement. It has several desirable
characteristics in terms of biocompatibility, bioactivity, hydrophilicity, radiopacity,
sealing ability and low solubility.
Diode laser in a young permanent tooth with traumatically exposed pulp has proved to be an
effective technique for Pulpotomy in an immature tooth. Therefore, the use of soft-tissue
diode lasers can influence the treatment outcome and should be seen as a predicable tool for
vital pulp therapy.